Streamlining Product Development with Platform Automation

Streamlining product development is a crucial hurdle for many biotech start-ups. If done correctly, this process can enhance efficiency, reduce time-to-market, and ensure consistency in product quality. In this talk, Jason Dowd, Global Cell Therapy Process Platform Lead at Bayer, will cover streamlining allogeneic product development using platform automation in both 2D and 3D systems. We’ll take a look at Bayer’s approach to industrializing cell therapy, diving into its comprehensive global program, which leverages automation and advanced bioprocess technology. Learn how this approach might inform your company timeline as you look ahead to streamline and scale your product development.

Register for the Livestream

About the Speaker

Jason Dowd, Global Cell Therapy Process Platform Lead, Bayer

Jason Dowd received his PhD from the University of British Columbia from the Michael Smith Biotech Lab and an MBA in Technology Management from the Open University in the UK. He has led the development of several biological products to marketing authorizations in major regulatory jurisdictions through pre-clinical, clinical and commercial stages. Recently at CCRM in Toronto as the Vice-President of Science and Technology, he led several research, development and GMP initiatives. Jason has returned to therapeutic product development with Bayer with a global role in allogeneic cell therapy platform development. Jason also has an adjunct professor role in the School of Engineering at McMaster University.